☰

Christina D. Drenberg, Ph.D. - Publications

Affiliations: 
2010 Medical Sciences University of South Florida, Tampa, FL, United States 
Area:
Oncology, Cell Biology, Pathology
Tree Info Grants Similar researchers PubMed Report error

16/24 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Drenberg CD, Shelat A, Dang J, Cotton A, Orwick SJ, Li M, Jeon JY, Fu Q, Buelow DR, Pioso M, Hu S, Inaba H, Ribeiro RC, Rubnitz JE, Gruber TA, et al. A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML. Nature Communications. 10: 2189. PMID 31097698 DOI: 10.1038/S41467-019-09917-0  0.325
2018 Pishas KI, Drenberg CD, Taslim C, Theisen ER, Johnson KM, Saund RS, Pop IL, Crompton BD, Lawlor ER, Tirode F, Mora J, Delattre O, Beckerle MC, Callen DF, Sharma S, et al. Therapeutic targeting of KDM1A/LSD1 in Ewing sarcoma with SP-2509 engages the endoplasmic reticulum stress response. Molecular Cancer Therapeutics. PMID 29997151 DOI: 10.1158/1535-7163.Mct-18-0373  0.38
2017 van Oosterwijk JG, Buelow DR, Drenberg CD, Vasilyeva A, Li L, Shi L, Wang YD, Finkelstein D, Shurtleff SA, Janke LJ, Pounds S, Rubnitz JE, Inaba H, Pabla N, Baker SD. Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia. The Journal of Clinical Investigation. PMID 29227282 DOI: 10.1172/Jci91893  0.373
2017 Drenberg C, Gibson AA, Pounds S, Shi L, Rhinehart D, Li L, Hu S, Du G, Nies AT, Schwab M, Pabla N, Blum W, Gruber TA, Baker SD, Sparreboom A. OCTN1 is a high-affinity carrier of nucleoside analogs. Cancer Research. PMID 28209616 DOI: 10.1158/0008-5472.Can-16-2548  0.396
2016 Drenberg CD, Buaboonnam J, Orwick SJ, Hu S, Li L, Fan Y, Shelat AA, Guy RK, Rubnitz J, Baker SD. Evaluation of artemisinins for the treatment of acute myeloid leukemia. Cancer Chemotherapy and Pharmacology. PMID 27125973 DOI: 10.1007/S00280-016-3038-2  0.31
2016 Drenberg CD, Hu S, Li L, Buelow DR, Orwick SJ, Gibson AA, Schuetz JD, Sparreboom A, Baker SD. ABCC4 Is a Determinant of Cytarabine-Induced Cytotoxicity and Myelosuppression. Clinical and Translational Science. PMID 26842729 DOI: 10.1111/Cts.12366  0.42
2016 Drenberg CD, Shelat A, Orwick SJ, Inaba H, Ribeiro RC, Rubnitz JE, Gruber TA, Guy RK, Baker SD. Abstract 4786: Integrated high-throughput screen to identify treatment leads for pediatric AML Cancer Research. 76: 4786-4786. DOI: 10.1158/1538-7445.Am2016-4786  0.395
2015 Dobrinski KP, Drenberg CD, Edelman JL, Buttermore ST, Mohamed M, Uversky VN, Hoffman MS, Nicosia SV, Kruk PA. Increased High Mobility Group Protein A2/SMAD3 Relates to Ovarian Cancer Progression Journal of Gynecology Research. 1. DOI: 10.15744/2454-3284.1.104  0.57
2013 Waibel M, Solomon VS, Knight DA, Ralli RA, Kim SK, Banks KM, Vidacs E, Virely C, Sia KC, Bracken LS, Collins-Underwood R, Drenberg C, Ramsey LB, Meyer SC, Takiguchi M, et al. Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. Cell Reports. 5: 1047-59. PMID 24268771 DOI: 10.1016/J.Celrep.2013.10.038  0.384
2013 Xie C, Drenberg C, Edwards H, Caldwell JT, Chen W, Inaba H, Xu X, Buck SA, Taub JW, Baker SD, Ge Y. Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51. Plos One. 8: e79106. PMID 24244429 DOI: 10.1371/Journal.Pone.0079106  0.416
2013 Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L, Payne-Turner D, Churchman M, Andersson A, Chen SC, McCastlain K, Becksfort J, Ma J, Wu G, Patel SN, ... ... Drenberg C, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nature Genetics. 45: 242-52. PMID 23334668 DOI: 10.1038/Ng.2532  0.313
2013 Drenberg CD, Fermanski B, Zatechka S, Fan Y, Orwick S, Janke L, Baker SD. Abstract C170: GDC-0941 inhibits cytarabine-induced PI3K/AKT signaling and promotes synergistic activity in acute myeloid leukemia. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C170  0.435
2012 Xie C, Edwards H, Drenberg C, Baker SD, Inaba H, Buck SA, Taub JW, Ge Y. Abstract 2739: Panobinostat potentiates the cytotoxic effects of ara-C and daunorubicin on acute myeloid leukemia cells through suppressing the DNA damage response Cancer Research. 72: 2739-2739. DOI: 10.1158/1538-7445.Am2012-2739  0.365
2010 Drenberg CD, Saunders BO, Wilbanks GD, Chen R, Nicosia RF, Kruk PA, Nicosia SV. Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer. Gynecologic Oncology. 117: 117-24. PMID 20071014 DOI: 10.1016/J.Ygyno.2009.12.011  0.626
2010 Drenberg CD, Bermudez Y, Nicosia SV, Kruk PA. Abstract 3208: Semaphorin 3F suppresses telomerase activity Cancer Research. 70: 3208-3208. DOI: 10.1158/1538-7445.Am10-3208  0.565
2009 Drenberg CD, Livingston S, Chen R, Kruk PA, Nicosia SV. Expression of Semaphorin 3F and Its Receptors in Epithelial Ovarian Cancer, Fallopian Tubes, and Secondary Müllerian Tissues. Obstetrics and Gynecology International. 2009: 730739. PMID 20041133 DOI: 10.1155/2009/730739  0.591
Low-probability matches (unlikely to be authored by this person)
2015 Drenberg CD, Paugh SW, Pounds SB, Shi L, Orwick SJ, Li L, Hu S, Gibson AA, Ribeiro RC, Rubnitz JE, Evans WE, Sparreboom A, Baker SD. Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. Clinical Pharmacology and Therapeutics. PMID 26663398 DOI: 10.1002/Cpt.315  0.296
2013 Drenberg CD, Baker SD, Sparreboom A. Integrating clinical pharmacology concepts in individualized therapy with Tyrosine Kinase inhibitors Clinical Pharmacology and Therapeutics. 93: 215-219. PMID 23419484 DOI: 10.1038/Clpt.2012.247  0.289
2016 Drenberg CD, Buelow DR, Pounds SB, Wang YD, Finkelstein D, Rahija RJ, Shurtleff SA, Rubnitz JE, Inaba H, Gruber TA, Klco JM, Baker SD. Transcriptome profiling of patient derived xenograft models established from pediatric acute myeloid leukemia patients confirm maintenance of FLT3-ITD mutation. Leukemia & Lymphoma. 1-4. PMID 27248844 DOI: 10.1080/10428194.2016.1187272  0.264
2022 Zhigarev D, Varshavsky A, MacFarlane AW, Jayaguru P, Barreyro L, Khoreva M, Dulaimi E, Nejati R, Drenberg C, Campbell KS. Lymphocyte Exhaustion in AML Patients and Impacts of HMA/Venetoclax or Intensive Chemotherapy on Their Biology. Cancers. 14. PMID 35884414 DOI: 10.3390/cancers14143352  0.244
2015 Drenberg CD, Pounds S, Shi L, Orwick S, Li L, Hu S, Gibson A, Ribeiro R, Rubnitz J, Sparreboom A, Baker SD. Abstract 5464: Host variation in OATP1B1 is associated with treatment outcome in pediatric AML Cancer Research. 75: 5464-5464. DOI: 10.1158/1538-7445.Am2015-5464  0.24
2019 Riether C, Chiorazzo T, Johnson AJ, Drenberg CD, Syed KW, Moshir M, Hultberg A, Leupin N, De Haard H, Ochsenbein AF. The Combination of the BCL-2 Antagonist Venetoclax with the CD70-Targeting Antibody Cusatuzumab Synergistically Eliminates Primary Human Leukemia Stem Cells Blood. 134: 3918-3918. DOI: 10.1182/blood-2019-127464  0.219
2012 Drenberg C, Zatechka S, Orwick S, Berk J, Baker S. 50 Establishment and Characterization of a C-Myc Mouse Model of Acute Myeloid Leukemia for Therapeutic Evaluation of Signaling Inhibitors European Journal of Cancer. 48: 17. DOI: 10.1016/S0959-8049(12)71848-8  0.174
2012 Zimmerman E, Hu S, Orwick S, Berk J, Li L, Drenberg C, Roberts M, Ramachandran A, Stewart C, Baker S. 386 Evaluation of Crenolanib (CP-868,596) for the Treatment of FLT3-ITD-positive AML European Journal of Cancer. 48: 117-118. DOI: 10.1016/S0959-8049(12)72184-6  0.111
Hide low-probability matches.